ArticleClinical pharmacology : advances and applications2026
Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study.
Article in Clinical pharmacology : advances and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-induced nausea and vomiting (CINV) remains a significant and distressing adverse effect of cancer treatment, adversely affecting patients' quality of life. Despite well-established international guidelines for antiemetic prophylaxis, variability in CINV incidence and guideline adherence persists across different regions and healthcare settings, particularly in low- and middle-income countries (LMICs). Objective: This study determined the incidence and associated factors of chemotherapy-induced nausea and vomiting (CINV) among adult cancer patients at Mbarara Regional Referral Hospital. Methods: A prospective observational study was conducted among 237 adult cancer patients receiving chemotherapy at the Mbarara Regional Referral Hospital. The MASCC Antiemesis Tool (MAT) was used to assess acute nausea and vomiting (≤24 hours) and delayed nausea and vomiting (>24 hours to 5 days), as well as any chemotherapy-induced nausea and vomiting (CINV; nausea and/or vomiting). A 5-day follow-up using the MAT tool for acute (≤24hours) and delayed (>24hours-5 days) CINV was conducted. Results: Among 237 participants, 66 (27.8%) and 136 (57.4%) experienced acute and delayed nausea, and 53 (22.4%) and 101 (42.6%) experienced acute and delayed vomiting; 67 (28.3%) and 136 (57.4%) had combined acute and delayed nausea and vomiting. Antiemetic prophylaxis guideline adherence was 73.4%, with 26.6% receiving non-guideline-compliant regimens. Independent associated factors for CINV were female sex (AOR = 2.0, 95% CI: 1.1-3.8; p = 0.026), moderate- (AOR = 21.2, 95% CI: 9.1-49.0; p < 0.001) and high-emetogenic chemotherapy (AOR = 22.6, 95% CI: 8.6-59.2; p < 0.001), and prior CINV (AOR = 6.1, 95% CI: 2.8-12.9; p < 0.001). Conclusion: Over half of the participants experienced delayed chemotherapy-induced nausea and vomiting, while nearly one-third experienced acute CINV. Adherence to guidelines for antiemetic prophylaxis was high at 73.4%. Key identified associated factors included female gender, moderate to highly emetogenic potential of chemotherapy regimens, and a history of CINV in this study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.